XML 87 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 20, 2025
Feb. 22, 2024
Jan. 31, 2025
May 31, 2024
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock option grants [1]                 3,733,000 3,618,000
Aggregate fair value of RSA granted                
Proceeds for issuance                 $ 447 $ 551
Subsequent Event [Member] | Employees [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock options granted 1,306,000                  
Weighted average exercise price $ 1.49                  
Restricted Stock [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Restricted stock awards granted                 1,600,000 550,000
2018 Long-Term Incentive Equity Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Number of shares reserved for issuance                 14,324,038  
Shares available for issue                 866,463  
2018 Long-Term Incentive Equity Plan [Member] | Employees and Directors [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock options granted   2,895,000                
Weighted average exercise price   $ 1.25                
2018 Long-Term Incentive Equity Plan [Member] | Subsequent Event [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Shares available for issue     4,018,163              
2018 Long-Term Incentive Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Weighted average estimated fair value                 $ 0.79 $ 0.88
2018 Long-Term Incentive Equity Plan [Member] | Restricted Stock [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Restricted stock awards granted       1,600,000            
Aggregate fair value of RSA granted       $ 1,500            
2018 Long-Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Subsequent Event [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Restricted stock awards granted 2,686,800                  
Aggregate fair value of RSA granted $ 4,000                  
Outside of 2018 Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock option grants                 523,300 523,300
Outside of 2018 Plan [Member] | Share-Based Payment Arrangement, Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Stock option grants                 523,300  
Outside of 2018 Plan [Member] | Restricted Stock [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Restricted stock awards granted                 50,000  
Employee Stock Purchase Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Number of shares reserved for issuance                 1,500,000  
Shares available for issue                 259,830  
Number of common stock purchased         136,056 511,884 276,213 231,987    
Proceeds for issuance         $ 94 $ 353 $ 275 $ 276    
Employee Stock Purchase Plan [Member] | Subsequent Event [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                    
Increase in number of shares available for issue     1,000,000              
[1] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.